Sandoz: ‘Replace Clinical Trials, And Harmonize’ To Bolster Biosimilar Development
Key Issue Discussed During Recent MFE Biosimilar Medicines Conference In Amsterdam
Executive Summary
Sandoz is feeling encouraged by what it perceives as a “much better understanding” from the European Medicines Agency for what it takes to develop biosimilars for vastly smaller opportunities – but is keen for payers to make sure such opportunities are commercially viable.